Literature DB >> 1885417

Antibacterial activity of lomefloxacin.

D A Leigh1, S Tait, B Walsh.   

Abstract

Lomefloxacin has marked activity against Gram-negative bacilli including Enterobacteriaceae, non-fermenting strains and Haemophilus influenzae with 98% of all isolates tested having MICs of 0.25 mg/l or less. Sixty-eight per cent of Pseudomonas aeruginosa strains were sensitive to 1 mg/l with a few strains resistant to 8 or 16 mg/l. Gram-positive cocci were more resistant, particularly streptococci, where the MICs vary between 1 and 8 mg/l. Bactericidal activity was similar to inhibitory activity and the effect of increasing serum concentrations and bacterial inocula was minimal. The MIC and MBC were increased in the presence of urine, particularly at an acid pH 5. Comparative MICs showed that lomefloxacin was more active than ofloxacin and pefloxacin, similar to norfloxacin but less active than ciprofloxacin for Gram-negative bacteria but not for Gram-positive cocci. Comparative studies with sensitivity disc concentrations showed that a 5 micrograms disc was more satisfactory than the 10 micrograms disc as the zone sizes were more suitable for routine testing. Solutions of lomefloxacin showed instability in bright sunlight when 52% of activity was lost in 1 h. Similar instability was shown in impregnated discs which lost up to 40% activity in 6 h exposure. Lomefloxacin showed a wide range of activity against Gram-negative bacteria including multiresistant strains and Pseudomonas spp. Gram-positive bacteria were less susceptible, with streptococci more resistant than staphylococci. Lomefloxacin is well absorbed after oral administration giving high blood and urine concentrations and its prolonged half-life means once daily dosing in the treatment of many types of bacterial infection may be possible.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1885417     DOI: 10.1093/jac/27.5.589

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  Bacterial challenges and evolving antibacterial drug strategy.

Authors:  B Watt; J G Collee
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

Review 2.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 3.  Impact of the fluoroquinolones on gastrointestinal flora.

Authors:  V Korten; B E Murray
Journal:  Drugs       Date:  1993       Impact factor: 9.546

4.  Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.

Authors:  Florian M E Wagenlehner; Stephan Wydra; Hajime Onda; Martina Kinzig-Schippers; Fritz Sörgel; Kurt G Naber
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

5.  Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV irradiation.

Authors:  M Matsumoto; K Kojima; H Nagano; S Matsubara; T Yokota
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

6.  Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light.

Authors:  K Marutani; M Matsumoto; Y Otabe; M Nagamuta; K Tanaka; A Miyoshi; T Hasegawa; H Nagano; S Matsubara; R Kamide
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

7.  Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers.

Authors:  K G Naber; U Theuretzbacher; M Kinzig; O Savov; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

Review 8.  Quinolone antibiotics.

Authors:  Thu D M Pham; Zyta M Ziora; Mark A T Blaskovich
Journal:  Medchemcomm       Date:  2019-06-28       Impact factor: 3.597

9.  Fluoroquinolone resistance during 2000-2005: an observational study.

Authors:  Richard J Ryan; Chris Lindsell; Paul Sheehan
Journal:  BMC Infect Dis       Date:  2008-05-24       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.